Your browser doesn't support javascript.
loading
Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis.
Casadei-Gardini, Andrea; Rimassa, Lorenza; Rimini, Margherita; Yoo, Changhoon; Ryoo, Baek-Yeol; Lonardi, Sara; Masi, Gianluca; Kim, Hyung-Don; Vivaldi, Caterina; Ryu, Min-Hee; Rizzato, Mario Domenico; Salani, Francesca; Bang, Yeonghak; Pellino, Antonio; Catanese, Silvia; Burgio, Valentina; Cascinu, Stefano; Cucchetti, Alessandro.
Afiliação
  • Casadei-Gardini A; School of Medicine, Vita-Salute San Raffaele University, Milan, Italy. casadeigardini@gmail.com.
  • Rimassa L; Unit of Oncology, Università Vita-Salute, IRCCS-San Raffaele Scientific Institute, via Olgettina 70, 20132, Milan, Milano, Italy. casadeigardini@gmail.com.
  • Rimini M; Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20090, Pieve Emanuele, Milan, Italy.
  • Yoo C; Medical Oncology and Hematology Unit, Humanitas Cancer Center, IRCCS Humanitas Research Hospital, Via Manzoni 56, 20089, Rozzano, Milan, Italy.
  • Ryoo BY; Department of Oncology and Hematology, Division of Oncology, University of Modena and Reggio Emilia, 4121, Modena, Italy.
  • Lonardi S; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Masi G; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Kim HD; Early Phase Clinical Trial Unit, Department of Oncology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
  • Vivaldi C; Medical Oncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
  • Ryu MH; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Rizzato MD; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
  • Salani F; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Bang Y; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Pellino A; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
  • Catanese S; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Burgio V; Medical Oncology Unit 1, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy.
  • Cascinu S; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
  • Cucchetti A; Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
J Cancer Res Clin Oncol ; 147(12): 3665-3671, 2021 Dec.
Article em En | MEDLINE | ID: mdl-33745079
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Piridinas / Terapia de Salvação / Carcinoma Hepatocelular / Anilidas / Neoplasias Hepáticas Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Cancer Res Clin Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália País de publicação: Alemanha
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Piridinas / Terapia de Salvação / Carcinoma Hepatocelular / Anilidas / Neoplasias Hepáticas Tipo de estudo: Clinical_trials Limite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: J Cancer Res Clin Oncol Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Itália País de publicação: Alemanha